What actually goes wrong.

The most common failure is also the least interesting, which is why it is under-discussed: the arithmetic is wrong.

• Milligram and microgram confusion. A protocol written in micrograms applied to a vial labeled in milligrams produces a thousand-fold error, and the direction of that error is not always obvious from how the person feels.
• Reconstitution arithmetic. Concentration depends on the diluent volume added. The same 5 mg vial reconstituted with 1 mL or with 3 mL yields doses that differ threefold at the same syringe marking.
• Syringe unit misreads. Insulin syringes are marked in units, not millilitres — 100 units to 1 mL on a U-100 syringe. Reading '10' as 10 mL rather than 10 units, or transposing the two scales, is a documented and repeated error.
• Label weight versus peptide weight. A vial's stated milligrams are gross powder mass; net peptide content is commonly 70–85% of it, so a dose calculated from the label overstates the active quantity delivered.

None of these require a bad actor or a contaminated lot. They happen to careful people working from a forum post at eleven at night.

Injection introduces material past every barrier the body has. Localized infection presents as increasing pain, redness, warmth and swelling at the site over a day or two, sometimes with fluctuance if an abscess forms; it can progress to cellulitis and, uncommonly, to systemic infection.

A pyrogenic reaction looks different: fever, shaking chills, headache and malaise beginning within minutes to hours of the injection, driven by endotoxin rather than by live organisms. It can occur with a preparation that contains no viable bacteria at all. Purity, sterility and endotoxin covers why these are separate properties and why a purity figure predicts neither.

Both warrant medical assessment rather than waiting it out. Neither is reliably preventable by inspecting a vial.

Independent testing programs have repeatedly found consumer products containing substances other than what their labels declared, including unapproved peptide ingredients.

• Operation Supplement Safety, the Department of Defense's supplement-education program, maintains ingredient advisories and has flagged unapproved peptide and secretagogue ingredients appearing in products marketed to service members, alongside its long-standing warnings that product labels can be inaccurate.
• The Banned Substances Control Group (BSCG), which tests supplements and certifies products for athletes, has reported findings of undeclared and unapproved peptide ingredients in products submitted for testing.
• Degradation is a separate route to the same outcome. Peptides are sensitive to heat, light, moisture and agitation; a lot that left the manufacturer intact can arrive after unrefrigerated transit with a materially reduced quantity of intact peptide and no way for the recipient to detect it.

The common thread is not that every product is wrong. It is that a purchaser has no mechanism for finding out which one is.

One example is worth stating precisely, because it is frequently repeated inaccurately. Clinical development of CJC-1295 in its long-acting drug-affinity-complex form was halted in July 2006 following the death of a participant during a trial program. That history is part of why the compound never completed development, and it is covered on our CJC-1295 page.

It is one documented event rather than a body of evidence, and it should be read as such. But it is the kind of history that a listing for the same compound will not mention.

The argument for physician oversight is not that a prescriber makes a compound safe. It is that monitoring is the step at which a problem becomes visible while it is still small.

• Baseline labs establish where you started, so a later change can be attributed rather than guessed at.
• Follow-up labs measure the effect instead of relying on how a given week felt — including effects that are asymptomatic until they are not, such as rising hematocrit or a shifting glucose picture.
• IGF-1 tracking is the objective readout for growth-hormone-axis therapy and the marker dose is titrated against, rather than titrating against perceived results.
• Interaction and contraindication review catches the medication, condition or finding that makes a plan inappropriate before it is started.
• The decision to stop. Discontinuation is a clinical outcome. Unmonitored use has no built-in moment at which anyone asks whether continuing is still the right call.